SLC6A3 and Parkinson disease: In the PARS study, hyposmic individuals with a baseline DAT deficit (below the 65% age-expected lowest putamen binding ratio) experienced a futher 4-year 20% decline in DAT binding (equaling to an annual 5% reduction similar to early PD) compared with 4%–5% in those with only intermediate or no DAT-deficit [43].